Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mesa, R.
Right arrow Articles by Tefferi, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mesa, R.
Right arrow Articles by Tefferi, A
Haematologica, Vol 91, Issue 3, 415-416
Copyright © 2006 by Ferrata Storti Foundation

Comparative Study

A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points

RA Mesa, H Powell, T Lasho, GW DeWald, R McClure, and A Tefferi

Serial analysis for the activating JAK2(V617F) mutation performed in 44 patients with myelofibrosis with myeloid metaplasia showed no interval change in 88% (22/25) of patients over a median interval of 18.6 months. The increase in JAK2 expression observed in three patients did not correspond to disease progression or leukemic transformation.


This article has been cited by other articles:


Home page
 BloodHome page
G. Barosi, G. Bergamaschi, M. Marchetti, A. M. Vannucchi, P. Guglielmelli, E. Antonioli, M. Massa, V. Rosti, R. Campanelli, L. Villani, et al.
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis
Blood, December 1, 2007; 110(12): 4030 - 4036.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. M. Vannucchi, E. Antonioli, P. Guglielmelli, A. Rambaldi, G. Barosi, R. Marchioli, R. M. Marfisi, G. Finazzi, V. Guerini, F. Fabris, et al.
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
Blood, August 1, 2007; 110(3): 840 - 846.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
R. Hoffman and D. Rondelli
Biology and Treatment of Primary Myelofibrosis
Hematology, January 1, 2007; 2007(1): 346 - 354.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. J. Campbell and A. R. Green
The Myeloproliferative Disorders
N. Engl. J. Med., December 7, 2006; 355(23): 2452 - 2466.
[Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.